Conference Documentation: Pharmaceutical Pricing and Reimbursement in the UK

Published by: SMI Publishing, Ltd

Published: Jun. 27, 2007

Table of Contents

Day One

8.30 Registration & Coffee

9.00 Chairman's Opening Remarks

Alain Vernot, President, APM International.

9.10 THE UK- STILL A PRIORITY ONE MARKET FOR PRICING & REIMBURSEMENT?

The reality of Reimbursement in the UK

UK Pharmacoeconomics as part of a global pricing strategy

Anne-Toni Rodgers, Director, Government Affairs & Public Policy, Baxter Healthcare.

9.50 WHERE IS DISTRIBUTION IN THE UK GOING?

Why manufacturers are seeking alternatives to the traditional wholesale network

Direct distribution

GSK’s and Pfizer’s agency distribution models

DoG concern over size of distribution margin

The growth of homecare

Where mail order is an option

Donald Macarthur, Global Pharmaceutical Business Analyst, .

10.30 Morning Coffee

11.00 HOW THE CSI’S RULING ON DUAL PRICING IN SPAIN WILL AFFECT UK P&R

Better controls on supply chain management

Should we pay attention to the ‘one product, one market’ argument?

Influence of Parallel Trade

Phill O'Neill, Consultant, Office Of Health Economics.

11.40 DEVISING EFFECTIVE PRICING STRATEGIES WHEN PREPARING FOR PRODUCT LAUNCH

Preparing for cost containment before launch

Peter Conway, Director, Health Economics, Wyeth Research.

12.20 Networking Lunch

1.50 PRICING & REIMBURSEMENT IN FRANCE: RECENT TRENDS

Prominent decisions in the last few months

Cutting drug costs in hospitals

Alain Vernot, President, APM International.

2.30 INITIAL RESULTS ON THE SUCCESS OF NICE’S FAST TRACK SINGLE TECHNOLOGY ASSESSMENT (STA) SYSTEM

Criteria to qualify for the STA

Reducing consultation to one round

Confronting doubts over speed

Meindert Boysen, Associate Director, N I C E (National Institute For Clinical Excellence).

Elisabeth George, Technical Advisor, N I C E (National Institute For Clinical Excellence).

3.10 Afternoon Tea

3.40 VALUE BASED PRICING: THE OFT’S RECOMMENDATIONS

What is the OFT proposing?

What are the implications

For big Pharma

For smaller companies

For biotech companies

For pharmaceutical R&D in the UK

Jim Furniss, Director, Pricing & Reimbursement, Bridgehead International.

4.20 GERMAN HEALTHCARE REFORM

Recent changes in the German pricing system

Will there be new cost-containment measures in Germany?

Will there be more competition in the German social healthcare system?

Dr Ann-Katrin Gonschior, Market Access & Reimbursement, Sanofi-Aventis .

5.00 Chairman’s Closing Remarks and Close of Day One

Abstract

• Peter Conway, Director, Market Access and Reimbursement, Wyeth
• Anne-Toni Rodgers, Director, Government Affairs and Public Policy, Europe, Wyeth
• Meindert Boysen, Associate Director, STA, NICE
• Dr Ann-Katrin Gonschior, Market Access and Reimbursement, Sanofi-Aventis
• Alain Vernot, President, APM International
• Donald Macarthur, Global Pharmaceutical Business Analyst
• Dr Robert Freeman, Principle, The Freeman Group LLC and former Executive Director, Public Policy, AstraZeneca
• Jim Furniss, Director, Pricing and Reimbursement, Bridgehead International
• Phill O'Neill, Consultant, Office of Health Economics and Business Intelligence Executive, Commercial and Trade Affairs, The Association of the British Pharmaceutical Industry (ABPI)
<

• AN ANALYSIS of the OFT’s recommendations, and the repercussions for pharma
• INCORPORATING Pharmacoeconomics as part of a dynamic pricing strategy
• THE EFFECTS of Category M on reimbursement of generic drugs
• CONFRONTING an increasingly hostile public policy towards product pricing
• CASE STUDY on changes in the German pricing system

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.